An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
What is the purpose of this trial?
This is a Bayesian adaptive dose-finding study in patients with primary or secondary myelofibrosis:
- who have failed therapy with ruxolitinib on the basis of intolerance or loss of efficacy,
- highly symptomatic (DIPSS risk score of Intermediate-1, Intermediate-2 or High Risk, and MPN-SAF TSS 2.0 of ≥10),
- and have splenomegaly (assessed by physical examination).
- Trial withCTI BioPharma Corp.
- Start Date09/22/2020
- End Date07/31/2022
- Last Updated07/15/2021
- Study HIC#2000021484